Approval · Notice of Compliance 32428 · 2023
REACTINE ALLERGY: Notice of Compliance 32428
Issued December 22, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32428
- Date
- December 22, 2023
- Company
- McNeil Consumer Healthcare, division of Johnson & Johnson Inc.Markham, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety update to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE ALLERGY | 02486954 | Marketed |
| REACTINE ALLERGY LIQUID GELS | 02368064 | Marketed |
| REACTINE FAST MELT JUNIOR | 02358352 | Marketed |
| REACTINE RAPID DISSOLVE | 02467577 | Marketed |
| REACTINE (10 MG) | 02223554 | Marketed |
| REACTINE (5 MG) | 02223546 | Marketed |
| REACTINE (CHILDREN'S SYRUP) | 02238337 | Marketed |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 10 MG per TAB
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- CETIRIZINE HYDROCHLORIDE 5 MG per 5ML
- CETIRIZINE HYDROCHLORIDE 10 MG per CAP